[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648475":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":26,"responsibleParty":41,"collaborators":26,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":26,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":26,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"Fujian Medical University Union Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexamethasone Prophylaxis Group","EXPERIMENTAL","At the end of surgery before abdominal closure, 10 mg dexamethasone diluted in 10 mL normal saline is sprayed onto the vagal nerve-rich areas: peritoneum around the esophageal hiatus, lesser omental sac, and surface of the hepatoduodenal ligament. Voice assessed daily (GRBAS scale + Praat recording) from postoperative day 1-10.",[13],"Drug: Dexamethasone",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Control Group","PLACEBO_COMPARATOR","At the end of surgery before abdominal closure, 10 mL normal saline alone is sprayed onto the same vagal nerve-rich areas. Voice assessed daily (GRBAS scale + Praat recording) from postoperative day 1-10. Patients who develop hoarseness (GRBAS Grade ≥2) are re-randomized to receive intravenous dexamethasone 5 mg or placebo daily for 3 days.",[19],"Drug: Saline (0.9% NaCl)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexamethasone","Dexamethasone 10 mg diluted in 10 mL normal saline, sprayed topically onto the vagal nerve-rich areas (esophageal hiatus, lesser omental sac, hepatoduodenal ligament) once at the end of surgery before abdominal closure.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Saline (0.9% NaCl)","10 mL normal saline sprayed topically onto the same vagal nerve-rich areas once at the end of surgery before abdominal closure. Patients in the placebo group who develop hoarseness (GRBAS Grade ≥ 2) will be re-randomized to receive intravenous dexamethasone 5 mg daily or placebo for 3 days.",[15],[32],{"name":33,"affiliation":5,"role":34},"ZHONGMENG LAI","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"KAIGE SHI","CONTACT","+86-18259992395","shikg2001@163.com",{"type":34,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"shikaige","Department of anesthesiology","100648475","intraperitoneal-dexamethasone-spraying-on-vagal-nerve-rich-areas-for-prevention-of-hoarseness-after-upper-abdominal-surgery-100648475",false,"NCT07722091","Intraperitoneal Dexamethasone Spraying on Vagal Nerve-Rich Areas for Prevention of Hoarseness After Upper Abdominal Surgery","Intraperitoneal Dexamethasone Spraying on Vagal Nerve-Rich Areas for Prevention of Hoarseness After Upper Abdominal Surgery: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 to 75 years, both sexes.\n* Elective abdominal surgery (including gastric, hepatobiliary, and pancreaticoduodenal surgery) under general anesthesia.\n* American Society of Anesthesiologists (ASA) physical status classification I-III.\n* Preoperative GRBAS Grade (G) score = 0 (no hoarseness).\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Need for systemic glucocorticoid therapy during hospitalization for other reasons.\n* Pre-existing hoarseness, vocal cord paralysis, or organic vocal cord lesions.\n* History of neck surgery, neck radiotherapy, or laryngeal surgery.\n* Known allergy to dexamethasone or other glucocorticoids.\n* Active peptic ulcer or gastrointestinal bleeding within 6 months prior to enrollment.\n* Uncontrolled diabetes mellitus or severe active infection.","ALL","18 Years","75 Years",{"count":55,"type":56},584,"ESTIMATED","INTERVENTIONAL",[59],"NA","The goal of this clinical trial is to evaluate whether intraoperative spraying of dexamethasone onto the abdominal vagal nerve-rich areas can prevent postoperative hoarseness in patients undergoing elective upper abdominal surgery. The main questions it aims to answer are:\n\n* Does intraoperative topical dexamethasone spraying reduce the incidence of postoperative hoarseness after upper abdominal surgery?\n* Does postoperative intravenous dexamethasone accelerate recovery in patients who develop hoarseness? Researchers will compare a dexamethasone group (intraoperative spraying of 10 mg dexamethasone in 10 mL normal saline) to a placebo group (intraoperative spraying of 10 mL normal saline alone) to see if dexamethasone reduces the rate of postoperative hoarseness.\n\nParticipants will:\n\n* Undergo voice assessment (GRBAS scale) and voice recording before surgery and daily for 10 days after surgery.\n* Be randomly assigned to receive either dexamethasone or placebo sprayed onto the surgical field at the end of the operation.\n* If hoarseness develops in the placebo group, be randomly assigned again to receive either intravenous dexamethasone (5 mg daily for 3 days) or placebo.",[62,63],"Hoarseness","Post Operative Complicaiton",[23,65,66],"Postoperative Hoarseness","Upper Abdominal Surgery","NOT_YET_RECRUITING","2026-07-18",{"date":70,"type":71},"2026-07-23","ACTUAL",{"date":73,"type":56},"2026-07-27",{"date":75,"type":56},"2027-03-01",{"name":5,"class":6}]